# US 2021/0332052 A1 · Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332052 A1
- Document ID: US20210332052A1
- Status: Published application
- Kind: A1
- Application number: 17/186,915
- Filed: 2021-02-26
- Published: 2021-10-28
- Earliest claimed: 2014-12-30
- Assignees: Valo Early Discovery, Inc.
- Applicants: Valo Early Discovery, Inc.
- Inventors: Stephanos Ioannidis; Adam Charles Talbot; Bruce Follows; Alexandre Joseph Buckmelter; Minghua Wang; Ann-Marie Campbell; Darby Rye Schmidt; David Joseph Guerin; Justin Andrew Caravella; R. Bruce Diebold; Anna Ericsson; David R. Lancia, JR.
- Web page: https://patentgrep.com/patent/US20210332052A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5′ and R6 are described herein.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
X1 is C, S, or S(O);
X2 is CR7 or N;
R1 is H, D, —OH, —SH, —NH2, —NH(C1-C4) alkyl, —N((C1-C4) alkyl)2, or F;
R2 is (C1-C8) alkyl, aryl, heteroaryl, (C3-C8) cycloalkyl, heterocyclyl, —NR10R11, or —OR10, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R8;
each R3 is independently at each occurrence selected from D, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, aryl, heteroaryl, (C3-C8) cycloalkyl, heterocyclyl, —CN, —OH, —C(O)R17, —C(O)OR17, —OC(O)OR17, —OC(O)NR17R18, —NR17R18, —NR17C(O)R18, —NR17C(O)OR18, —C(O)NR17R18, —NR17C(O)NR17R18, —S(O)qNR17R18, —S(O)qR17R18, —NR17S(O)qR17R18, or halogen, wherein alkyl is optionally substituted with one or more substituents independently selected from —OH or —NH2;
or two R3 together when on adjacent carbons form a (C3-C5) cycloalkyl optionally substituted with one or more R19; or two R3 together form a (C3-C8) spirocycloalkyl optionally substituted with one or more R19; or two R3 together form a spiroheterocyclyl optionally substituted with one or more R19; or two R3 together when on adjacent carbons form an aryl ring optionally substituted with one or more R19; or two R3 together when on adjacent carbons form an heteroaryl ring optionally substituted with one or more R19;
R4 is (C1-C6) alkyl, —(C0-C3) alkylene-aryl, heteroaryl, (C3-C8) cycloalkyl, CD3, or heterocyclyl, wherein aryl, heteroaryl, heterocyclyl and cycloalkyl are optionally substituted with one or more R12;
R5 and R5′ are independently H, D, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or halogen; or
R5 and R5′ together form a (C3-C6) cycloalkyl or heterocyclyl ring optionally substituted with one or more substituents independently selected from halogen, —CN, (C1-C6) alkyl, —OH, —CH2OH, —(C0-C2)-alkylene-O(C1-C6) alkyl, or —(C0-C2)-alkylene-NR17R18;
R6 is independently H, D, halogen, —CN, —NR17R18, (C1-C6) alkyl, (C1-C6) alkoxy, or —OH when X2 is N;
R7 is H, D, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, aryl, heteroaryl, —CN, or —NR10R11, wherein aryl and heteroaryl is optionally substituted with one or more R10;
each R8 is independently at each occurrence selected from D, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, —(C1-C3)-alkylene-O(C1-C6) alkyl, —(C0-C4)-alkylene-aryl, —(C0-C4)-alkylene-heteroaryl, (C3-C10) cycloalkyl, heterocyclyl, —(C0-C4)-alkylene-O-aryl, —(C0-C4)-alkylene-O-heteroaryl, —O—(C3-C5)cycloalkyl, —S-heteroaryl, halogen, —CN, —C(O)R10, —CO(O)R10, —C(O)NR10R11, —S(O)qR10, —S(O)qNR10R11, —NR10S(O)qR11, —(C0-C3)-alkylene-NR10R11, —NR10C(O)R11, —NR10C(O)C(O)R11, —NR10C(O)NR10R11, —P(O)((C1-C6)alkyl)2, —P(O)(aryl)2, —SiMe3, SF5, or —OH, wherein alkyl, alkylene, aryl, heteroaryl, and heterocyclyl are optionally substituted with one or more R9;
or two R8 together when on adjacent carbons form an aryl ring optionally substituted with one or more R9; or two R8 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R9; or two R8 together when on adjacent carbons form a heterocyclyl ring optionally substituted with one or more R9;
each R9 is independently at each occurrence selected from D, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C8) cycloalkyl, halogen, aryl, —OH, —CN, —C(O)R10, —C(O)NR10R11, —NR10C(O)R11, —NR10R11, —S(O)qR10, —S(O)qNR10R11, —NR10S(O)qR11, oxo, —P(O)((C1-C6)alkyl)2, —P(O)(aryl)2, —SiMe3, SF5, —O-aryl, CN, or —O-heteroaryl, wherein alkyl, aryl, and cycloalkyl are optionally substituted with one or more substituents independently selected from (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, halogen, aryl, —NR14C(O)R15, —NR14S(O)qR15, —OH or —CN;
or two R9 together when on adjacent carbons form an aryl ring; or two R9 together when on adjacent carbons form a heteroaryl ring; or two R9 together when on adjacent carbons form a (C3-C10) cycloalkyl ring;
each R10 and R11 is independently at each occurrence selected from H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, —(C0-C3) alkylene-aryl, —(C0-C4) alkylene-(C3-C5) cycloalkyl, —(C0-C4) alkylene-heterocyclyl, —(C0-C4) alkylene-heteroaryl, or —CN, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more substituents independently selected from (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C3-C5) cycloalkyl, heterocyclyl, aryl, —S(O)q(C1-C3) alkyl, —S(O)qNR14R15, —NR14R15, —NR14C(O)R15, halogen, —OH, or —CN;
or R10 and R11 together form a heterocyclyl ring optionally substituted with one or more substituents selected from oxo, —C(O)(C1-C3) alkyl or —NR14NR15;
each R12 is independently at each occurrence selected from D, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C3-C5) cycloalkyl, aryl, heteroaryl, —O-aryl, —O-heteroaryl, —O-heterocyclyl, —O—(C3-C5)cycloalkyl, —S(O)qR10, —(CH2)pC(O)OR10, —C(O)NR14R10, —S(O)qNR14R15, —NR14R15, —NR14C(O)NR14R15, —NR14C(O)OR10, —NR14SOqR10, —NR14COR10, halogen, —P(O)((C1-C6)alkyl)2, —P(O)(aryl)2, —SiMe3, SF5 or —OH, wherein alkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl are optionally substituted with one or more R13;
each R13 is independently at each occurrence selected from D, (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, halogen, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, heterocyclyl, heteroaryl, aryl, —OR14, —C(O)R14, —C(O)NR14R15, —NR14R15, —S(O)qR14, —NR14S(O)qR15, —S(O)qNR14R15, —NR14C(O)NR14R15, —NR14C(O)OR15, —P(O)((C1-C6)alkyl)2, —P(O)(aryl)2, —SiMe3, SF5 or —CN, wherein alkyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl are substituted with one or more substituents independently selected from (C1-C6) alkyl, —NR14C(O)R15, —OH, —CN, —C(O)R14, or —NR14R15;
or two R13 together when on adjacent carbons form a heterocyclyl ring optionally substituted with one or more R16; or two R13 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R16; or two R13 together with the carbon to which they are attached can form a spiroheterocyclyl optionally substituted with one or more R16;
each R14 and R15 are independently at each occurrence selected from H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, —(C1-C4) alkylene-(C3-C8) cycloalkyl, —(C0-C4) alkylene-heterocyclyl, —(C0-C4) alkylene-aryl, —(C0-C4) alkylene-heteroaryl, or —CN, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more R16;
or R14 and R15 together form a heterocyclyl ring optionally substituted with one or more R16;
each R16 is independently at each occurrence selected from D, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, (C1-C6) haloalkoxy, —C(O)(C1-C3) alkyl, —NHC(O)(C1-C4) alkyl, —CN, —CH2CN, —CR10R11NR10R11, oxo, —NR10R11, —S(O)q(C1-C6) alkyl, —C(O)NR10R11, —S(O)qNR10R11, —NR10C(O)R10R11, —NR10C(O)NR10R11, or —OH;
or two R16 together when on adjacent carbons form an aryl ring; or two R16 together when on adjacent carbons form a spiroheterocyclyl ring;
each R17 and R18 is at each occurrence independently H or (C1-C6) alkyl;
R19 is independently at each occurrence H, D, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —CN, or —NR17R18;
m is 0, 1 or 2;
n is 0, 1, 2 or 3;
p is 0, 1, or 2; and
each q is 0, 1, or 2.

### Claim 15 (depends on 14)

The compound of claim 14, having Formula (Ia):
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 14)

The compound of claim 14, having Formula (Ib):
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 14)

The compound of claim 14, having Formula (Ic):
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 14)

The compound of claim 14, having Formula (Id):
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 14)

The compound of claim 14, having Formula (Ie):
or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 14)

The compound of claim 14, having Formula (If):
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 14)

The compound of claim 14, having Formula (Ig):
or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 14)

The compound of claim 14, having Formula (Ih):
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 14)

The compound of claim 14, having Formula (Ii):
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 14)

The compound of claim 14, having Formula (Ij):
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 14)

A pharmaceutical composition comprising, a compound of claim 14 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 14)

A method of treating a disease or disorder associated with modulation of USP7 comprising, administering to a patient in need thereof an effective amount of a compound of claim 14.

### Claim 27 (depends on 14)

A method of inhibiting USP7 comprising administering to a patient in need thereof an effective amount of a compound of claim 14.

### Claim 28 (depends on 14)

A method of treating cancer, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 14.

### Claim 29 (depends on 14)

A method of treating a neurodegenerative disease, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 14.

### Claim 30 (depends on 14)

A method of treating a viral infection and disease, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 14.

### Claim 31 (depends on 14)

A method of treating an inflammatory disease or condition, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 14.

### Claim 32 (depends on 14)

A method of inducing cell cycle arrest, apoptosis in tumor cells, and/or enhanced tumor specific T-cell immunity, the method comprising contacting the cells with an effective amount of a compound of claim 14.
